|This article needs additional citations for verification. (June 2015)|
|Traded as||NASDAQ: ACOR FWB: CDG|
|Headquarters||Ardsley, New York, United States|
Andrew R. Blight
|Revenue||US$292.2 Million (FY 2011)|
|US$35.1 Million (FY 2011)|
|US$30.6 Million (FY 2011)|
|Total assets||US$379.5 Million (FY 2011)|
|Total equity||US$205.2 Million (FY 2011)|
Number of employees
|328 (February, 2012) |
Acorda Therapeutics is a biotechnology company based in Ardsley, New York, USA. The company develops drugs to improve therapies that improve neurological function in people with multiple sclerosis, spinal cord injury and other disorders of the central nervous system. Acorda manufactures and markets the drugs Zanaflex, Ampyra and Qutenza in the United States.
As of December 31, 2013[update], the members of the board of directors of Acorda Therapeutics were: Ron Cohen, Barry Greene, Peder K. Jensen, John P. Kelley, Sandra Panem, Lorin J. Randall, Steven M. Rauscher, and Ian F. Smith.
Products on the market
|This section requires expansion. (January 2010)|
Products under development
|This section is empty. You can help by adding to it. (January 2010)|
- Acorda FAQ
- "Acorda Therapeutics 2011 Annual Report - Form 10-K - February 28, 2012." (PDF). secdatabase.com. Retrieved May 16, 2012.
- Acorda 2008 10-K Annual report
- Acorda Therapeutics 2013 Annual Report
|This article about a medical, pharmaceutical or biotechnological corporation or company is a stub. You can help Wikipedia by expanding it.|
|This biotechnology article is a stub. You can help Wikipedia by expanding it.|